Umer Raffat
Stock Analyst at Evercore ISI Group
(1.31)
# 3,659
Out of 5,141 analysts
20
Total ratings
52.94%
Success rate
-9.3%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $43.21 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $14.01 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $0.47 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $57.92 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $31.91 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $24.50 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $34.22 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $11.42 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $27.88 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $18.12 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.10 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $25.28 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $960 | $13.55 | +6,984.87% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $374.75 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $8.50 | +464.71% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $172.19 | - | 1 | Feb 23, 2017 |
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $43.21
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $14.01
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.47
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $57.92
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $31.91
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $24.50
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $34.22
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $11.42
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $27.88
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $18.12
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.10
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $25.28
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $960
Current: $13.55
Upside: +6,984.87%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $374.75
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $8.50
Upside: +464.71%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $172.19
Upside: -